VolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy

Reuters11-14

<a href="https://laohu8.com/S/VNRX">VolitionRX Ltd</a>. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy

VolitionRX Ltd. (NYSE: VNRX) has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583578780?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 16:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583578780","market":"nz","top_or_hot":-1,"title":"VolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRX Ltd. (NYSE: VNRX) has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 16:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VNRX\">VolitionRX Ltd</a>. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VolitionRX Ltd. (NYSE: VNRX) has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VNRX","symbol_name":"VolitionRX Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL3F2lhl:1","article_id":"2583578780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583578780","pubTimestamp":1763107862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VolitionRX Ltd.  has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.Disclaimer: This news brief was created by Publi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VNRX":"VolitionRX Ltd","BK4198":"医疗保健用品"},"translate_title":"VolitionRX Ltd.推出公司演示文稿，重点介绍表观遗传诊断和全球许可战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNRX":0.9},"content_text":"VolitionRX Ltd. unveils corporate presentation highlighting epigenetic diagnostics and global licensing strategy\n    \n\n        VolitionRX Ltd. (NYSE: VNRX) has released a corporate presentation highlighting its focus on commercial partnerships, IP licensing, and the development of low-cost diagnostic tests for cancer and sepsis. The company emphasizes its expertise in quantifying nucleosomes and measuring chromatin fragments, with products adaptable to various diagnostic workflows. VolitionRX outlines its strategy to monetize intellectual property through licensing agreements that provide upfront payments, milestone payments, and recurring revenue from royalties. The company targets broad geographic reach and large installed bases in its licensing and partnering efforts, with ongoing commercial validation through partnerships such as those with Antech and Fujifilm. VolitionRX is pursuing multiple licensing deals in the human health sector and continues to target unmet needs in both human and veterinary diagnostics. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583578780","isCrawlerRequest":true}